Benefits
Digestive comfort in adults with gut complaints
In 77 adults with self-reported digestive complaints and no diagnosed gut disorder, 500 mg a day for 8 weeks lowered the total digestive symptom score more than placebo, a medium effect. Both groups improved, mostly in the first 4 weeks, and no single symptom cluster (pain, reflux, diarrhea, indigestion, constipation) differed from placebo. The one trial was funded by the maker.
Knee pain and walking tests
In 101 adults aged 45 to 70 with knee joint wear, 500 mg twice a day for 8 weeks lowered the main knee pain score and 0 to 10 knee pain ratings more than placebo, and improved two walking tests. Knee symptoms, daily function, sport function, knee quality of life and general wellbeing scores did not differ. The one trial was funded by the maker.
Gut bacteria and small intestine breath tests
The digestive trial also tested whether the extract changes gut bacteria, a co-primary outcome. In the 50 people with stool data, bacterial makeup did not differ from placebo at the phylum level or for any selected bacterium, a diversity difference at the genus level disappeared after adjusting for baseline, and hydrogen and methane breath test results did not change in either group.
Anxiety ratings measured alongside gut symptoms
In the digestive trial, anxiety and total scores on a depression, anxiety and stress questionnaire fell more on the extract than on placebo, while depression and stress scores did not differ. These were secondary measures in people recruited for gut complaints, not for mood, so they do not show an effect on mood.
Blood curcuminoid levels after a single dose
In a maker-funded crossover study in 17 healthy men, a single dose of about 2 g curcuminoids gave higher blood levels of free and total curcuminoids than a standard 95 percent extract at the same curcuminoid dose. These are absorption markers, not health outcomes, and free curcumin stayed in the low nanogram per milliliter range.
Mechanism of action
Dispersible oleoresin format
The trial papers state that polar resins in the oleoresin base let the lipophilic curcuminoids disperse in water, which the maker links to better access to absorptive surfaces. In the single-dose study, blood curcuminoid levels were higher than with a standard extract. An independent study of other curcumin products argues that absorption claims should rest on free curcumin, which stays at low levels in the blood.
Curcumin and inflammatory signaling
Curcumin is reported to affect NF-kB, COX-2 and inflammatory cytokines, and in animal and cell models it protected cartilage. These pathways come from laboratory and animal work. Neither published trial of this extract measured inflammatory markers in the blood, so an effect on inflammation in people has not been tested with it.
Proposed gut mechanisms
The digestive trial tested whether symptom changes ran through gut bacteria or small intestine bacterial overgrowth and found no change in either, and no link between diversity changes and symptom changes. The authors suggested gut barrier function, inflammation, neurotransmitter activity and gut sensitivity as untested alternatives.
Clinical trials
Randomized, double-blind, placebo-controlled parallel trial; one 500 mg Curcugen capsule (about 250 mg curcuminoids) daily at bedtime for 8 weeks, microcrystalline cellulose placebo; registered ACTRN12619001236189; funded by DolCas Biotech, which supplied the capsules and was not involved in data collection or analysis; one author was director of medical and scientific affairs at DolCas, and the lead author, of Clinical Research Australia, disclosed honoraria or trial grants from nutraceutical companies (Lopresti et al. 2021, BMC Complement Med Ther)
79 adults aged 18 to 65 with self-reported digestive complaints of mild to moderate severity (GSRS average 2 to 5) and no diagnosed gut disease (people with inflammatory bowel disease or functional gut disorders such as IBS were excluded); 77 (38 curcumin, 39 placebo) were analyzed for symptom outcomes.
Total digestive symptom score (GSRS), the primary outcome, fell more on Curcugen than on placebo (p = 0.021, effect size 0.57); both groups improved, mostly by week 4, and the curcumin group started higher (2.91 versus 2.65), so week 8 totals ended close together (2.10 versus 2.18); no GSRS subscale differed between groups. The co-primary gut microbiota outcome, analyzed in only 50 participants, was null at the phylum level and for selected bacteria, and breath tests for small intestine bacterial overgrowth did not change. As secondary results, DASS-21 anxiety (p = 0.023) and total scores fell more on Curcugen, while depression and stress scores did not differ; an SF-36 pain difference disappeared after adjusting for baseline. Adverse effects were mild and did not differ (11 on placebo, 6 on curcumin).
Randomized, double-blind, placebo-controlled parallel trial; one 500 mg Curcugen capsule twice daily with food for 8 weeks, microcrystalline cellulose placebo; prospectively registered ACTRN12620000976987; funded by DolCas Biotech, which supplied the capsules and took part in study design and manuscript writing but not data collection or analysis; one author was director of medical and scientific affairs at DolCas, and the lead author is managing director of Clinical Research Australia, a contract research organization funded by nutraceutical companies (Lopresti et al. 2021, Nutrients)
101 adults aged 45 to 70 with knee osteoarthritis diagnosed by a doctor (self-reported, with X-ray confirmation reported by all) and knee pain of at least 6 out of 10 (51 curcumin, 50 placebo); 96 completed.
The KOOS knee pain score, the primary outcome, improved more on Curcugen (about 12 versus 6 points, p = 0.009, effect size 0.39), and more people on Curcugen reached a minimal clinically important change (20 of 51 versus 9 of 47 in Table 3, or 39 versus 19 percent, although the Results text prints 33 percent). The between-group difference in KOOS pain change was about 6.5 points (95% CI 0.2 to 12.8), below the 10 point change the authors cite as clinically meaningful. Knee pain ratings (0 to 10, past week; the printed between-group CI crosses zero despite the reported p = 0.001), the JOA score, the timed up-and-go test and the 6 minute walk test also improved more, while the other KOOS subscales, PROMIS-29, the 30 second chair stand and the 40 meter walk did not differ. Pain medication use fell in 37 versus 13 percent, which the authors say needs confirmation. Adverse events were 5 on curcumin and 10 on placebo.
Randomized, double-blind, two-way crossover, single oral dose comparative bioavailability study under fasting conditions, 7 day washout; Curcugen versus a 95 percent curcuminoid reference extract, each giving about 2 g of curcuminoids; registered CTRI/2019/07/020467; DolCas Biotech provided funding, two authors were employees of Olene Life Sciences, the patent holder, and one of DolCas, while the PubMed abstract states no conflicts of interest (Panda et al. 2021, Medicine (Baltimore))
Healthy men aged 18 to 45; 18 were planned and 17 were included in the pharmacokinetic analysis.
Free curcumin peaked at about 1.2 ng/mL with Curcugen versus about 0.07 ng/mL with the reference, and exposure over time (AUC) was 39 times higher; total curcuminoid AUC was 52.5 times higher and tetrahydrocurcumin 31 times higher. The fold differences rest on very low reference values (free curcumin AUC about 0.07 ng h/mL on the standard extract). These are blood level markers after one dose, not health outcomes. Two mild adverse events were reported: a raised eosinophil count on Curcugen that resolved, and a raised ALT on the reference product.